Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown.To evaluate the relation of irAEs to nivolumab efficacy in NSCLC.In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who were...